Європейський Союз -
англійська -
EMA (European Medicines Agency)
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies.zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
imlygic 100million plaque forming units1ml solution for injection vials
amgen ltd - talimogene laherparepvec - solution for injection - 100mega u/1ml
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
imlygic 1million plaque forming units1ml solution for injection vials
amgen ltd - talimogene laherparepvec - solution for injection - 1mega u/1ml
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
venclexta 10mg tablets
imported (united states) - venetoclax - oral tablet - 10mg
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
venclexta 50mg tablets
imported (united states) - venetoclax - oral tablet - 50mg
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
venclexta 100mg tablets
imported (united states) - venetoclax - oral tablet - 100mg
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
venclexta tablets starting pack
imported (united states) - not applicable
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
lynparza 100mg tablets
astrazeneca uk ltd - olaparib - tablet - 100mg
Велика Британія -
англійська -
MHRA (Medicines & Healthcare Products Regulatory Agency)
lynparza 150mg tablets
astrazeneca uk ltd - olaparib - tablet - 150mg
Європейський Союз -
англійська -
EMA (European Medicines Agency)
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, - venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (cll) in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor. venclyxto monotherapy is indicated for the treatment of cll in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b cell receptor pathway inhibitor.,